Low cellular fibronectin (<2.7 µg/mL) was associated with a nearly 4-fold increased risk of bleeding (HR 3.85, 95% CI 1.06-14.00) in rivaroxaban-treated atrial fibrillation patients during 49 months follow-up.
Cohort (n=185)
No
Does low cellular fibronectin increase the risk of bleeding in patients with atrial fibrillation on long-term rivaroxaban therapy?
Low plasma cellular fibronectin levels independently predict an increased risk of bleeding in patients with atrial fibrillation receiving long-term rivaroxaban therapy, potentially due to the formation of looser fibrin networks.
Effect estimate: HR 3.85 for bleeding comparing lowest cFn quartile (< 2.7 µg/mL) to highest quartile (> 4.5 µg/mL) (95% CI 95% CI 1.06-14.00)
p-value: p=0.04
Our results suggest that low cFn levels might help identify patients with AF at increased bleeding risk during long-term anticoagulation, and this association could partly be related to the formation of looser fibrin networks.
Glądys et al. (Wed,) conducted a cohort in Patients with atrial fibrillation on long-term rivaroxaban anticoagulation (n=185). Rivaroxaban anticoagulation vs. No comparator group (observational cohort) was evaluated on Risk of bleeding (major and non-major clinically relevant bleeding) during follow-up (HR 3.85 for bleeding comparing lowest cFn quartile (< 2.7 µg/mL) to highest quartile (> 4.5 µg/mL), 95% CI 95% CI 1.06-14.00, p=0.04). Low cellular fibronectin (<2.7 µg/mL) was associated with a nearly 4-fold increased risk of bleeding (HR 3.85, 95% CI 1.06-14.00) in rivaroxaban-treated atrial fibrillation patients during 49 months follow-up.